Skip to main content

MW 473.4 Da, Purity >98%. Novel, selective, cell membrane permeable clathrin inhibitor. Competitively inhibits clathrin terminal domain to selectively inhibit clathrin mediated endocytosis (CME) (IC50 = 12 μM for inhibition of amphiphysin association of clathrin TD). Interferes with receptor mediated endocytosis (RME), entry of HIV and synaptic vesicle recycling.

Be the first to review this product! Submit a review

Images

Chemical Structure - Pitstop® 2, Novel cell-permeable clathrin inhibitor (AB120687), expandable thumbnail
  • Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (AB120687), expandable thumbnail
  • Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (AB120687), expandable thumbnail

Publications

Key facts

Purity
> 98%
Form
Solid
Molecular weight
473.4 Da
Molecular formula
C20H13BrN2O3S2
PubChem identifier
137254289
Nature
Synthetic

Recommended products

MW 473.4 Da, Purity >98%. Novel, selective, cell membrane permeable clathrin inhibitor. Competitively inhibits clathrin terminal domain to selectively inhibit clathrin mediated endocytosis (CME) (IC50 = 12 μM for inhibition of amphiphysin association of clathrin TD). Interferes with receptor mediated endocytosis (RME), entry of HIV and synaptic vesicle recycling.

Key facts

Purity
> 98%
PubChem identifier
137254289
Solubility

Soluble in DMSO. Please refer to the Protocol Booklet for more information.

Biochemical name
2-(1-Naphthylsulfonylamino)-5-[(Z)-4-bromobenzylidene]-2-thiazoline-4-one
Biological description

Novel, selective, cell membrane permeable clathrin inhibitor. Competitively inhibits clathrin terminal domain to selectively inhibit clathrin mediated endocytosis (CME) (IC50 = 12 μM for inhibition of amphiphysin association of clathrin TD). Interferes with receptor mediated endocytosis (RME), entry of HIV and synaptic vesicle recycling.

Canonical SMILES
C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)N=C3NC(=O)C(=CC4=CC=C(C=C4)Br)S3
Isomeric SMILES
C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)N=C3NC(=O)/C(=C/C4=CC=C(C=C4)Br)/S3
InChI
InChI=1S/C20H13BrN2O3S2/c21-15-10-8-13(9-11-15)12-17-19(24)22-20(27-17)23-28(25,26)18-7-3-5-14-4-1-2-6-16(14)18/h1-12H,(H,22,23,24)/b17-12-
InChIKey
CGDLWHGPJPVPDU-ATVHPVEESA-N
IUPAC name
N-[(5Z)-5-[(4-bromophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]naphthalene-1-sulfonamide

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions, The product can be stored for up to 12 months

Notes

High concentrations of Pitstop 2™ may interfere with fluorescence imaging due to a low emittance of the compound in the green channel. This fluorescence is not usually detectable if the cells have been first fixed and washed prior to imaging.

Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. Pitstop® is a trademark of Freie Universitat Berlin, Newcastle Innovation Ltd. and Children's Medical Research Institute.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Chemical Structure - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687), expandable thumbnail

    Chemical Structure - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687)

    2D chemical structure image of ab120687, Pitstop® 2, Novel cell-permeable clathrin inhibitor

  • Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687), expandable thumbnail
    Dutta D et al. PLoS One. 2012; 7(9): e45799. doi: 10.1371/journal.pone.0045799 Reproduced under the Creative Commons license https://creativecommons.org/publicdomain/zero/1.0/

    Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687)

    Hela cells were preincubated with DMSO (0.1%) or different doses of pitstop 2 (ab120687) ranging from 5 μM to 30 μM. Cells were then allowed to internalize Alexa594-Transferrin and antibodies to MHCI in the presence or absence of the drug for 30 min. After internalization, surface antibody was removed by low pH acid wash. Cells were then labeled with secondary antibodies to detect trasnferrin and MHCI.

    Credit: Dutta D et al. PLoS One. 2012; 7(9): e45799. doi: 10.1371/journal.pone.0045799

  • Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687), expandable thumbnail
    Von Kleist L et al., Cell. 2011 Aug 5;146(3):471-84. Fig, 3(A-E)., doi: 10.1016/j.cell.2011.06.025.

    Functional Studies - Pitstop® 2, Novel cell-permeable clathrin inhibitor (ab120687)

    A) Pitstop® 2 reversibly inhibits Tf uptake. After 15 min preincubation HeLa cells were incubated with Alexa Fluor® 568-Tf in the presence of DMSO or 30 µM Pitstop 2 for 15 min. Tf uptake is seen to resume after washout of the drug for 1 hr. Scale bar, 10 mm. B) Reversibility and dose dependence of Pitstop® 2-mediated inhibition of Tf uptake. Data represent SEM (n = 3 independent experiments; *p < 0.05, ***p < 0.0001). C) Pitstop® 2 inhibits EGF uptake. HeLa cells pretreated with 30 µM pitstop 2 or DMSO for 15 min were incubated for 15 min with Alexa Fluor® 488-EGF in the continued presence of inhibitor. Data represent SEM (n = 3 independent experiments; ***p < 0.0001). D) Pitstop 2 does not interfere with AP-2-mediated cargo sequestration into CCPs. TIRF microscopy images of Cos7 cells pretreated with DMSO or 30 µM Pitstop 2 for 15 min were incubated with Alexa Fluor® 488-EGF at 8oC in the continued presence of inhibitor and immunostained for AP-2a (red). Scale bar, 4 mm. E) Pearson’s

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com